Cellular cholesterol movement in cardiovascular disease

心血管疾病中的细胞胆固醇运动

• 批准号: 10613974
• 负责人: PETER J TONTONOZ
• 金额: $ 67.08万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10613974
• 关键词: Adrenal Cortex; Adrenal Glands; Area; Arterial Fatty Streak; Atherosclerosis; Binding; Binding Proteins; Biochemical; Biological; Biology; Biotin; Bone Marrow Transplantation; Cardiovascular Diseases; Cell membrane; Cells; Chemicals; Chemistry; Chimeric Proteins; Cholesterol; Cholesterol Esters; Collaborations; Data; Development; Disease; Electrons; Endoplasmic Reticulum; Esterification; Foam Cells; Functional disorder; Genes; Gonadal structure; HDL receptor; Health; High Density Lipoproteins; Homeostasis; Image; Impairment; In Vitro; Label; Laboratories; Lesion; Lipids; Macrophage; Mammalian Cell; Mass Spectrum Analysis; Measures; Mediator; Membrane; Membrane Proteins; Metabolic Diseases; Metabolism; Molecular; Movement; Mus; Pathway interactions; Physiology; Proteins; Recording of previous events; Research Personnel; Role; SR-BI receptor; Series; Signal Pathway; Stable Isotope Labeling; Sterols; Technology; Testing; Therapeutic Intervention; Tissues; atherogenesis; chemoproteomics; cholesterol control; crosslink; defined contribution; humoral immunity deficiency; imaging modality; in vivo; lipid metabolism; live cell microscopy; member; mimetics; novel; novel strategies; particle; response; uptake

Project 3: Sterol Transport Pathways in Cardiovascular Disease ABSTRACT The objective of Project 3 is to define fundamental mechanisms that regulate cellular lipid flux and to elucidate their impact on systemic metabolism. Dissecting signaling pathways that govern how cells store, transport, and metabolize lipids is expected to uncover new opportunities for therapeutic intervention in metabolic disease. Although nonvesicular cholesterol transport has long been hypothesized to be critical for lipid homeostasis in mammalian cells, the underlying mechanisms have remained obscure. We have discovered a novel transporter called Aster-B that appears to fill this important gap in our understanding of sterol transport. Aster-B is a previously uncharacterized protein that facilitates the direct transport of cholesterol from the plasma membrane (PM) to the ER. We propose a series of molecular, cell biological, and mouse studies to investigate the roles of the Aster-B cholesterol transport pathway in physiology and disease. Aim 1 is to elucidate the role of Aster-B in cellular cholesterol transport, efflux, and esterification. We identified Asterb as a novel cholesterol-responsive LXR target gene. Gain or loss of Aster-B alters cholesterol distribution and impairs cholesterol ester synthesis in response to cholesterol loading. Using biochemical approaches and complementary imaging modalities including electron and live-cell microscopy, we will define the mechanism of action of Aster-B and its role in macrophage sterol flux. Aim 2 is to determine the impact of Aster-B on sterol transport in vivo. Preliminary data indicate that Asterb is most highly expressed in macrophages, adrenal gland, and gonads. We will determine the effect of loss of Aster-B expression on whole-body and tissue-specific lipid homeostasis. We hypothesize that Aster-B is a critical mediator of cellular cholesterol transport downstream of the HDL receptor SR-BI. Aim 3 is to define the contribution of the macrophage Aster pathway to atherosclerosis. The LXR pathway is one of the strongest known determinants of atherosclerotic lesion development. Our observation that Aster-B expression is regulated by LXRs suggests that Aster-dependent cholesterol transport may impact macrophage foam cell formation and the development of atherosclerosis. We will test the impact of gain or loss of Aster function on macrophage cholesterol uptake and efflux. We will perform bone marrow transplant studies into LDLR-deficient mice to test the impact of Aster-B deficiency on lesion formation. Aim 4 is to identify additional components of the Aster pathway. We will perform protein-interaction screens using a biotin proximity labeling strategy. We will perform a chemoproteomic screen using HDL particles loaded with a cholesterol-mimetic probe that can be crosslinked to proteins and retrieved using a click-chemistry handle. This application leverages the unique and complementary strengths of each member of our PPG, bringing together a range of approaches and technological capabilities that would be unavailable to any single investigator. Understanding the molecular pathways that control cholesterol movement in macrophages is central to the overall theme of this PPG application and will advance our understanding of both physiology and pathophysiology.

项目3：心血管疾病中的固醇转运途径 摘要 项目3的目标是确定调节细胞脂质通量的基本机制，并阐明 它们对全身代谢的影响。剖析控制细胞如何储存、运输和 代谢脂质有望揭示代谢疾病治疗干预的新机会。 虽然非囊泡胆固醇转运长期以来一直被假设为是关键的脂质稳态， 哺乳动物细胞中，潜在的机制仍然不清楚。我们发现了一种新的传送器 Aster-B似乎填补了我们对固醇转运理解的重要空白。Aster-B是一种 促进胆固醇从质膜直接转运的一种以前未知的蛋白质 (PM)去急诊室我们提出了一系列的分子，细胞生物学和小鼠研究，以调查的作用， Aster-B胆固醇转运途径在生理和疾病中作用。目的1是阐明Aster-B在 细胞胆固醇转运、流出和酯化。我们将Asterb确定为一种新型的胆固醇敏感性 LXR靶基因。Aster-B的获得或丧失改变了胆固醇的分布，并损害了胆固醇酯的合成。 对胆固醇负荷的反应。使用生化方法和互补成像模式 包括电子显微镜和活细胞显微镜，我们将定义Aster-B的作用机制及其在 巨噬细胞固醇通量目的2是确定Aster-B对体内固醇转运的影响。初步数据 表明Asterb在巨噬细胞、肾上腺和性腺中表达最高。我们将确定 Aster-B表达缺失对全身和组织特异性脂质稳态的影响。我们假设 Aster-B是HDL受体SR-BI下游细胞胆固醇转运的关键介质。目标3 是确定巨噬细胞Aster通路对动脉粥样硬化的作用。LXR途径是一种 动脉粥样硬化病变发展的最强已知决定因素。我们观察到Aster-B表达 提示Aster依赖的胆固醇转运可能影响巨噬细胞泡沫细胞 动脉粥样硬化的形成和发展。我们将测试Aster功能的获得或丧失对 巨噬细胞胆固醇摄取和流出。我们将对低密度脂蛋白受体缺乏的患者进行骨髓移植研究。 小鼠以测试Aster-B缺乏对病变形成的影响。目标4是确定 Aster途径我们将使用生物素邻近标记策略进行蛋白质相互作用筛选。我们将 使用装载有胆固醇模拟探针的HDL颗粒进行化学蛋白质组学筛选， 与蛋白质交联并使用点击化学手柄取回。该应用程序利用了独特的 我们的PPG每个成员的优势互补，汇集了一系列方法， 任何一个调查员都无法获得的技术能力。了解分子 控制巨噬细胞中胆固醇运动的途径是本PPG总体主题的核心 应用，并将促进我们对生理学和病理生理学的理解。